Correction: Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain (Proceedings of the National Academy of Sciences of the United States of America (2014) 111, 45 (16071-16076) DOI: 10.1073/pnas.1313420110);Intracranial microcapsule chemotherapy delivery for the localized treatment of rodent metastatic breast adenocarcinoma in the brain

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 45, 2014, Pages 16071-16076

  Upadhyay, Urvashi M ^a   Tyler, Betty ^b   Patta, Yoda ^c   Wicks, Robert ^b   Spencer, Kevin ^c   Scott, Alexander ^c   Masi, Byron ^c   Hwang, Lee ^b   Grossman, Rachel ^b   Cima, Michael ^c,d   Brem, Henry ^b   Langer, Robert ^c,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Brain; Chemotherapy; Intracranial; Metastases; Microcapsule

Indexed keywords

CASPASE 3; DOXORUBICIN; POLYMER; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CASP3 PROTEIN, RAT; DACARBAZINE; MICROCAPSULE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN METASTASIS; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; LIQUID CRYSTAL; MICROCAPSULE; NONHUMAN; RAT; TREATMENT OUTCOME; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; FEMALE; FISCHER 344 RAT; HUMAN; MAMMARY NEOPLASMS, EXPERIMENTAL; METABOLISM; METASTASIS; PATHOLOGY; SECONDARY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAPSULES; CASPASE 3; DACARBAZINE; DOXORUBICIN; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; NEOPLASM PROTEINS; RATS; RATS, INBRED F344;

EID: 84909595113     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1600771113     Document Type: Erratum

References (35)

1. De Angelis LM (2001) Brain tumors. N Engl J Med 344(2):114-123.
2. Raghavan R, et al. (2006) Convection-enhanced delivery of therapeutics for brain disease, and its optimization. Neurosurg Focus 20(4):E12.
3. Brem H, Langer R (1996) Polymer-based drug delivery to the brain. Sci Med (Phila) 3:52-61.
4. Lesniak MS, Brem H (2004) Targeted therapy for brain tumours. Nat Rev Drug Discov 3(6):499-508.
5. Sawyer AJ, Piepmeier JM, Saltzman WM (2006) New methods for direct delivery of chemotherapy for treating brain tumors. Yale J Biol Med 79(3-4):141-152.
6. Brem H, et al.; The Polymer-brain Tumor Treatment Group (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012.
7. Santini JT, Jr, Cima MJ, Langer R (1999) A controlled-release microchip. Nature 397(6717):335-338.
8. Santini J, Jr, Richards AC, Scheidt R, Cima MJ, Langer R (2000) Microchips as controlled drug-delivery devices. Angew Chem Int Ed Engl 39(14):2396-2407.
9. McGirt MJ, et al. (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110(3):583-588.
10. Lechapt-Zalcman E, et al. (2012) O (6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide. Cancer 118(18):4545-4554.
11. Westphal M, et al. (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-oncol 5(2):79-88.
12. Scott AW, et al. (2011) Intracranial microcapsule drug delivery device for the treatment of an experimental gliosarcoma model. Biomaterials 32(10):2532-2539.
13. Ewend MG, Sampath P, Williams JA, Tyler BM, Brem H (1998) Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43(5):1185-1193.
14. Nussbaum ES, Djalilian HR, Cho KH, Hall WA (1996) Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 78(8):1781-1788.
15. Rusciano D, Burger MM (1993) Mechanisms of metastases. Molecular Genetics of Nervous System Tumors, eds Levine AJ, Schmidek HH (Wiley, New York).
16. Debinski W, Tatter SB (2009) Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother 9(10):1519-1527.
17. Bindal RK, Sawaya R, Leavens ME, Lee JJ (1993) Surgical treatment of multiple brain metastases. J Neurosurg 79(2):210-216.
18. Bindal AK, et al. (1996) Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84(5):748-754.
19. Eichler AF, Loeffler JS (2007) Multidisciplinary management of brain metastases. Oncologist 12(7):884-898.
20. Patchell RA, et al. (2006) Radiosurgery plus whole-brain radiation therapy for brain metastases. JAMA 296(17):2089-2090.
21. Patchell RA, et al. (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322(8):494-500.
22. Pirzkall A, et al. (1998) Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16(11):3563-3569.
23. Paek SH, Audu PB, Sperling MR, Cho J, Andrews DW (2005) Reevaluation of surgery for the treatment of brain metastases: Review of 208 patients with single or multiple brain metastases treated at one institution with modern neurosurgical techniques. Neurosurgery 56(5):1021-1034.
24. Rosner D, Nemoto T, Lane WW (1986) Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58(4):832-839.
25. Stark AM (2010) Neurosurgical treatment of breast cancer metastases to the neurocranium. Patholog Res Int 2011(2010):549847.
26. Chang JE, Robins HI, Mehta MP (2007) Therapeutic advances in the treatment of brain metastases. Clin Adv Hematol Oncol 5(1):54-64.
27. Abrey LE, et al. (2001) A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 53(3):259-265.
28. Christodoulou C, et al.; Hellenic Cooperative Oncology Group (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 12(2):249-254.
29. Laginha KM, Verwoert S, Charrois GJ, Allen TM (2005) Determination of doxorubicin levels in whole tumor and tumor nuclei in murine breast cancer tumors. Clin Cancer Res 11(19 Pt 1):6944-6949.
30. Ortho Biotech Products, LP (2007) DOXIL Product Information. Available at stage.doxil.com/shared/product/doxil/prescribing-information.pdf. Accessed April 19, 2007.
31. Mantha A, et al. (2005) A novel rat model for the study of intraosseous metastatic spine cancer. J Neurosurg Spine 2(3):303-307.
32. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C (1997) Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23(1):35-61.
33. Strasser JF, Fung LK, Eller S, Grossman SA, Saltzman WM (1995) Distribution of 1, 3-bis (2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants. J Pharmacol Exp Ther 275(3):1647-1655.
34. Fung LK, et al. (1998) Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58(4):672-684.
35. Ewend MG, et al. (1996) Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 56(22):5217-5223.